Published in Cancer Res on November 01, 2005
Macropinocytosis: searching for an endocytic identity and role in the uptake of cell penetrating peptides. J Cell Mol Med (2007) 1.65
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Sox2 is essential for formation of trophectoderm in the preimplantation embryo. PLoS One (2010) 1.26
CPPsite: a curated database of cell penetrating peptides. Database (Oxford) (2012) 1.21
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin Dev Immunol (2012) 0.91
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic. Chonnam Med J (2015) 0.87
LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines. Vaccine (2011) 0.83
Cellular immunotherapy using dendritic cells against multiple myeloma. Korean J Hematol (2012) 0.83
A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clin Exp Immunol (2008) 0.83
Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother (2014) 0.79
Low cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells. Biomaterials (2015) 0.78
Major Histocompatibility Complex (MHC) Class I Processing of the NY-ESO-1 Antigen Is Regulated by Rpn10 and Rpn13 Proteins and Immunoproteasomes following Non-lysine Ubiquitination. J Biol Chem (2016) 0.77
Dendritic cell cancer vaccines: from the bench to the bedside. Rambam Maimonides Med J (2014) 0.77
Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. Oncotarget (2016) 0.76
Dendritic Cell Therapies for Hematologic Malignancies. Mol Ther Methods Clin Dev (2017) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
The molecular classification of multiple myeloma. Blood (2006) 8.77
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med (2006) 7.89
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) 3.22
Multiple myeloma: clinical review and diagnostic imaging. Radiology (2004) 3.12
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol (2010) 3.09
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Treatment of multiple myeloma. Blood (2003) 2.34
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol (2006) 2.32
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis (2008) 2.26
Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect. Bone (2012) 2.24
Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol (2004) 2.16
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis (2010) 2.10
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res (2013) 2.02
Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res (2004) 1.98
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood (2013) 1.98
Familial myeloma. N Engl J Med (2008) 1.96
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005) 1.95
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood (2012) 1.93
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood (2008) 1.93
Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med (2004) 1.85
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol (2010) 1.84
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J (2003) 1.81
International prognostic scoring system for Waldenstrom macroglobulinemia. Blood (2009) 1.81
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A (2010) 1.78
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol (2002) 1.74
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica (2010) 1.73
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 1.73
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood (2005) 1.71
Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis (2011) 1.70
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood (2014) 1.68
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell (2013) 1.67
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol (2010) 1.66
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood (2002) 1.65
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood (2011) 1.60
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood (2014) 1.59
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell (2006) 1.58
Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica (2006) 1.58
Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol (2012) 1.57
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol (2005) 1.56
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood (2009) 1.56